Enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia (AG221-AML-005): a single-arm, phase 1b and randomised, phase 2 trial-Reference-Cited by-同舟云学术

Enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia (AG221-AML-005): a single-arm, phase 1b and randomised, phase 2 trial

Published:2021-11 Issue:11 Volume:22 Page:1597-1608
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

DiNardo Courtney D,Schuh Andre C,Stein Eytan M,Montesinos Pau,Wei Andrew H,de Botton Stéphane,Zeidan Amer M,Fathi Amir T,Kantarjian Hagop M,Bennett John M,Frattini Mark G,Martin-Regueira Patricia,Lersch Frederik,Gong Jing,Hasan Maroof,Vyas Paresh,Döhner Hartmut

Funder

Bristol-Myers Squibb Co

Publisher

Elsevier BV

Subject

Oncology

Reference28 articles.

1. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel;Döhner;Blood,2017

2. Acute myeloid leukemia, version 3.2019, NCCN Clinical Practice Guidelines in Oncology;Tallman;J Natl Compr Canc Netw,2019

3. Acute myeloid leukemia;Döhner;N Engl J Med,2015

4. Cytogenetics and gene mutations influence survival in older patients with acute myeloid leukemia treated with azacitidine or conventional care;Döhner;Leukemia,2018

5. The prognostic impact and stability of isocitrate dehydrogenase 2 mutation in adult patients with acute myeloid leukemia;Chou;Leukemia,2011

Cited by 90 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A study to assess the efficacy of enasidenib and risk-adapted addition of azacitidine in newly diagnosed IDH2-mutant AML;Blood Advances;2024-01-12

2. High-Risk Neutropenic Fever and Invasive Fungal Diseases in Patients with Hematological Malignancies;Microorganisms;2024-01-06

3. The future paradigm of HMA + VEN or targeted inhibitor approaches: sequencing or triplet combinations in AML therapy;Hematology;2023-12-08

4. Emerging and Future Targeted Therapies for Pediatric Acute Myeloid Leukemia: Targeting the Leukemia Stem Cells;Biomedicines;2023-12-07

5. Genetic alterations that deregulate RB and PDGFRA signaling pathways drive tumor progression in IDH2-mutant astrocytoma;Acta Neuropathologica Communications;2023-11-27